IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

https://www.globenewswire.com/news-release/2024/08/12/2928370/0/en/IN8bio-Solidifies-Position-as-a-Clinical-Leader-of-Gamma-Delta-T-Cell-Therapy-in-Oncology-with-100-of-Treated-AML-Patients-in-Complete-Remission-and-Receives-FDA-Guidance-for-Regis.html

NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq:INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer, today announced updated positive clinical data from both of the Company’s Phase 1 investigator-sponsored trials of INB-100 for hematological malignancies and INB-200 for GBM. The Company has also completed a Type B meeting with the FDA and received guidance on the registrational path to advance INB-100 for the treatment of AML.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.